Form 4: Delcath Systems Director Steven Salamon Reports Acquisition of 400,000 Shares

Director Steven Salamon reports the acquisition of 400,000 common shares of Delcath Systems through the exercise of warrants by Rosalind Opportunities Fund I L.P.

Summary

• On May 5, 2025, Steven Salamon, a director of Delcath Systems, Inc., reported a transaction involving the acquisition of 400,000 common shares.
• The shares were acquired through the exercise of warrants by Rosalind Opportunities Fund I L.P.
• The price per share was $10.
• Following the transaction, Mr. Salamon beneficially owns 3,413,468 shares indirectly through Rosalind Advisors Inc., the advisor to the Rosalind Funds.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a transaction. It doesn't inherently convey positive or negative sentiment, but rather reports a factual event.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry. Monitoring these transactions can provide insights into management's perspective on the company's prospects.

Stakeholder Impact

• The transaction may have a minor impact on shareholders as it reflects insider activity, but the overall impact is likely minimal.

Key Dates

Keywords

Delcath Systems, Steven Salamon, Director, Form 4, Beneficial Ownership, Common Shares, Rosalind Advisors, Rosalind Funds, Warrants, Acquisition